Intuitive Surgical Q2 Earnings Beat, Outlook Held

Intuitive Surgical Inc. (Nasdaq: ISRG) reported Q2 earnings on July 16, 2026, that topped estimates as global procedure growth and recurring revenue drove results. Management maintained its 2026 da Vinci procedure-growth forecast while noting moderated U.S. growth and ongoing challenges in China.

Quarter Results and Profitability

For the quarter ended June 30, 2026, Intuitive Surgical reported revenue of $2.9 billion, a 19.0% increase from the prior year. GAAP net income was $818 million, with diluted earnings per share of $2.29. On a non-GAAP basis, net income reached $1.0 billion and diluted EPS was $2.80, reflecting a 28.0% year-over-year increase. The non-GAAP operating margin stood at 42.0%. Recurring revenue, which includes instruments, accessories, services, and leasing, totaled $2.5 billion, or 85.0% of total sales. Results included a $28 million net benefit from International Emergency Economic Powers Act tariff refunds, equal to $0.08 per diluted share.

Management attributed the adjusted EPS gain to the revenue mix and margin profile, with recurring revenue supporting operating leverage. The tariff refund provided a modest profit boost, while disciplined cost control and investment contributed to margin expansion.

The company ended the quarter with $8.6 billion in cash, cash equivalents, and investments. It repurchased approximately 0.9 million shares for $0.4 billion during the period. Management signaled plans to continue share buybacks alongside funding research, development, and platform rollouts.

Procedures, Systems, and Outlook

Worldwide procedures assisted by Intuitive platforms grew about 16.0% year over year in Q2, with da Vinci procedures up roughly 15.0% and Ion procedures increasing about 36.0%. The company placed 468 da Vinci surgical systems during the quarter, including 246 da Vinci 5 systems. Management highlighted ongoing adoption of the da Vinci SP and Ion platforms.

Intuitive maintained its 2026 worldwide da Vinci procedure-growth forecast at approximately 14.0–15.0%, expecting continued double-digit global expansion despite moderated U.S. growth and challenges in China. The faster growth of Ion procedures relative to da Vinci reflected traction for the newer platform within the installed base.

The results underscore a business driven by a high recurring-revenue mix and expanding margins, supported by a strong cash position and active buybacks. This financial flexibility supports the rollout of new systems and longer-term adoption in international markets.